You are here: Industry Insights > ADC

News List

Lonza Enters Long-term Bioconjugation Collaboration contractpharma
December 03, 2020
Will construct two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates at its Visp site.
Abenza Upgrades Chemistry GMP Suites contractpharma
November 25, 2020
Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites.
Lonza Opens Facility for ADC Payload Manufacturing contractpharma
November 06, 2020
Lonza, a specialty CDMO partner to the biopharma industry, has inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload) manufacturing at the Visp, Switzerland site.
Samsung Biologics Expands in China contractpharma
November 05, 2020
Samsung Biologics has entered into a partnership with GeneQuantum Healthcare, a China biotech company, to jointly develop an antibody drug conjugate (ADC) for the treatment of non-small-cell lung carcinoma (NSCLC), triple-negative breast cancer (TNBC)...
CStone and LegoChem to jointly develop novel antibody drug conjugate pharmaceutical-technology
October 30, 2020
CStone Pharmaceuticals and LegoChem Biosciences (LCB) have signed a licensing agreement for the development and commercialisation of a potential antibody-drug conjugate (ADC), LCB71.
Iksuda Therapeutics exercises licensing rights from University of Goettingen pharmatimes
October 16, 2020
UK-based biotech company Iksuda Therapeutics has executed its option to secure exclusive worldwide rights to develop a new class of tumour-activated prodrug payloads from the University of Goettingen.
Exelixis, NBE join forces for discovery and development of ADCs for cancer pharmaceutical-business-review
September 24, 2020
Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific ...
$65 million expansion to HPAPI manufacturing facility europeanpharmaceuticalreview
September 24, 2020
The expansion will be specifically designed to manufacture high-potency active pharmaceutical ingredients (HPAPIs) and complex antibody-drug conjugates (ADCs).
MilliporeSigma Expands HPAPI and ADC Mfg. Capabilities contractpharma
September 18, 2020
$65 million investment to expand facility near Madison, WI will allow large-scale manufacturing of increasingly potent compounds.
Exelixis and Catalent Enter ADC Partnership contractpharma
September 17, 2020
Collaboration, license and exclusive option agreement to develop antibody-drug conjugates leveraging SMARTag bioconjugation technology.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page